Bookmark and Share

Compound Summary for: CID 54726191

dolutegravir

Also known as: S/GSK1349572; 1051375-16-6; GSK1349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; S-349572; CHEBI:76010; Tivicay
Molecular Formula: C20H19F2N3O5   Molecular Weight: 419.378766   InChIKey: RHWKPHLQXYSBKR-BMIGLBTASA-N
Dolutegravir is indicated for HIV-1 infection for adults and children and adolescents ?12 years of age and weighing ?40 kg. It is marketed as Tivicay as dolutegravir sodium. 52.6 mg of dolutegravir sodium is equivalent to 50 mg dolutegravir free acid. FDA approved on August 12, 2013.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Biomedical Effects and Toxicity
Safety and Handling
Exposure Standards and Regulations
Literature
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _